Talazoparib is a potent oral poly(ADP-ribose) polymerase (PARP) inhibitor indicated for the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated HER2-negative locally advanced… Read more
Talazoparib is a potent oral poly(ADP-ribose) polymerase (PARP) inhibitor indicated for the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer. By inhibiting PARP enzymes, this therapeutic agent prevents the repair of single-strand DNA breaks, leading to cytotoxic effects in tumor cells with homologous recombination deficiency. This category provides essential reference standards, including the active pharmaceutical ingredient, its salt forms such as the tosylate, and related impurities like the nitroso derivative. These materials are critical for researchers and analytical chemists involved in impurity profiling, method validation, and rigorous quality control testing of pharmaceutical formulations. Furthermore, stable isotope-labelled compounds are available to serve as high-precision internal standards in mass spectrometry-based bioanalytical assays, ensuring accurate quantification and characterization during drug development and stability studies.